Vicore Pharma Holding

Vicore Pharma is a clinical-stage pharmaceutical company dedicated to developing a new class of drugs called Angiotensin II type 2 receptor (AT2R) agonists. The company's lead candidate, buloxibutid, is currently in Phase 2 clinical development for idiopathic pulmonary fibrosis (IPF), showing promising results in stabilizing lung function. Vicore's pipeline also includes follow-on AT2R agonists like C106, targeting pulmonary arterial hypertension and other fibrotic conditions. Headquartered in Sweden, the company leverages its deep expertise in the renin-angiotensin system to address high unmet needs in rare lung diseases. Vicore is publicly traded on the Nasdaq Stockholm exchange.